Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Thoracic Cancer|August 27, 2020
Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysisHisao Imai, Hiroyuki Minemura, Takayuki Kishikawa, et al.
Frontiers in Oncology|February 6, 2023
Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancerSatoshi Wasamoto, Hisao Imai, Takeshi Tsuda, et al.
Scientific Reports|November 27, 2023
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinibOu Yamaguchi, Norimitsu Kasahara, Hiroshi Soda, et al.
JAMA Oncology|March 7, 2024
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung CancerYoko Tsukita, Takehiro Tozuka, Kohei Kushiro, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2021
Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort studyDaichi Fujimoto, Satoru Miura, Kenichi Yoshimura, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|March 1, 2023
Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancerKyoichi Kaira, Ou Yamaguchi, Ichiro Naruse, et al.
Scientific Reports|July 13, 2022
Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancerOu Yamaguchi, Kyoichi Kaira, Ichiro Naruse, et al.
The Lancet. Oncology|April 13, 2019
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Tatsuro Fukuhara, Naoki Furuya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2025
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834Satoru Miura, Hiroshi Tanaka, Toshihiro Misumi, et al.
The Lancet. Respiratory Medicine|August 29, 2021
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trialYosuke Kawashima, Tatsuro Fukuhara, Haruhiro Saito, et al.
Pageof 10